Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Genuine Parts Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Genuine Parts Company trades at $124.41 (market cap $17.71B). The key difference: Genuine Parts Company is far larger — about 3.9× ACADIA Pharmaceuticals Inc.'s market cap, and Genuine Parts Company pays a 3.3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GPC | |
|---|---|---|
Market Cap | $4.49B | $17.71B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $149.26 |
52-Week Low | $20.06 | $92.47 |
Enterprise Value | $3.69B | $23.92B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GPC trades at $128.67, down 2.94% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results due July 21, 2026. Financials show revenue growth to $24.3B in 2025 but a sharp decline in net income margin to 0.24%, while the P/E ratio of 292.41 reflects high valuation relative to earnings. A dividend of $1.06 per share is scheduled for payment on July 2, 2026.
The outlook is cautious due to weak profitability and high P/E, but analyst consensus is a Buy with a $133 price target, suggesting modest upside. Risks include earnings volatility and competitive pressures in the automotive parts sector. The stock's near-term direction hinges on Q2 2026 earnings, with support at $126 and resistance at $131.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
